Cite
HARVARD Citation
Schadendorf, D. et al. (2019). Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). European journal of cancer. pp. 144-153. [Online].